BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32860655)

  • 1. Pralatrexate-based therapy induced response in an adolescent with refractory hepatosplenic T-cell lymphoma.
    Dhir A; Hill B; Waite ES; Cairo MS; Xavier AC
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28460. PubMed ID: 32860655
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatosplenic alphabeta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gammadelta hepatosplenic T-cell lymphoma.
    Suarez F; Wlodarska I; Rigal-Huguet F; Mempel M; Martin-Garcia N; Farcet JP; Delsol G; Gaulard P
    Am J Surg Pathol; 2000 Jul; 24(7):1027-32. PubMed ID: 10895827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rare cause of Fever, hepatosplenomegaly, and thrombocytopenia: hepatosplenic gamma/delta T-cell lymphoma.
    Albayrak M; Balcik OS; Alan S; Dıncer SL; Yüksel MK; Albayrak A
    Pathol Oncol Res; 2011 Jun; 17(2):421-3. PubMed ID: 21197592
    [No Abstract]   [Full Text] [Related]  

  • 4. Rare variety of T-cell lymphoma.
    Pednekar S; Morge V; Rawal S; Korivi D; Ramteke V; Naik K
    J Assoc Physicians India; 2011 Oct; 59():667-8. PubMed ID: 22479752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive multifocal leukoencephalopathy in a patient with hepatosplenic T cell lymphoma.
    González de la Aleja J; Giménez-Mesa E; Posada IJ; Gonzalo-Martínez JF; Bustelo R; Escudero L
    Eur Neurol; 2006; 55(1):44-5. PubMed ID: 16479120
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytotoxic T-lymphocyte differentiation and cytogenetic alterations in gammadelta hepatosplenic T-cell lymphoma and posttransplant lymphoproliferative disorders.
    Salhany KE; Feldman M; Peritt D; Nowell PC
    Blood; 1997 May; 89(9):3490-1. PubMed ID: 9129060
    [No Abstract]   [Full Text] [Related]  

  • 7. Post-transplant hepatosplenic T-cell lymphoma successfully treated with HyperCVAD regimen.
    Tey SK; Marlton PV; Hawley CM; Norris D; Gill DS
    Am J Hematol; 2008 Apr; 83(4):330-3. PubMed ID: 17876769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine.
    Jaeger G; Bauer F; Brezinschek R; Beham-Schmid C; Mannhalter C; Neumeister P
    Ann Oncol; 2008 May; 19(5):1025-6. PubMed ID: 18375525
    [No Abstract]   [Full Text] [Related]  

  • 9. [T-cell rich B-cell lymphoma associated with hemophagocytic syndrome].
    Dommann-Scherrer C; Zimmermann D; Hassam S; Odermatt BF; Risti B; Maurer R
    Verh Dtsch Ges Pathol; 1992; 76():122-5. PubMed ID: 1283241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatosplenic αβ T-Cell Lymphoma as Second Malignancy in Young Adult Patient With Previously Undiagnosed Ataxia-Telangiectasia.
    Jacobs MF; Anderson B; Opipari VP; Mody R
    J Pediatr Hematol Oncol; 2020 Aug; 42(6):e463-e465. PubMed ID: 31259827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatosplenic T cell lymphoma responsive to 2'-deoxycoformycin therapy.
    Bennett M; Matutes E; Gaulard P
    Am J Hematol; 2010 Sep; 85(9):727-9. PubMed ID: 20652973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and treatment outcomes of 14 patients with hepatosplenic γ δ T-cell lymphoma.
    Wang Q; Jiang Y; Zhu Q; Duan Y; Chen X; Xu T; Jin Z; Li C; Wu D; Huang H
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3441-3445. PubMed ID: 33856526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Microcellular lung carcinoma in patient with hepatosplenic T-cell lymphoma: a case report].
    Kalac M; Ostojić S; Gasparov S; Planinc-Peraica A; Dominis M; Jaksić B
    Lijec Vjesn; 2006; 128(3-4):76-8. PubMed ID: 16808095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature.
    Domm JA; Thompson M; Kuttesch JF; Acra S; Frangoul H
    J Pediatr Hematol Oncol; 2005 Nov; 27(11):607-10. PubMed ID: 16282893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatosplenic gammadelta T-cell lymphoma with ring chromosome 7, an isochromosome 7q equivalent clonal chromosomal aberration.
    Tamaska J; Adam E; Kozma A; Gopcsa L; Andrikovics H; Tordai A; Halm G; Bereczki L; Bagdi E; Krenacs L
    Virchows Arch; 2006 Oct; 449(4):479-83. PubMed ID: 16941150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatosplenic gamma/delta T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features.
    Vega F; Medeiros LJ; Bueso-Ramos C; Jones D; Lai R; Luthra R; Abruzzo LV
    Am J Clin Pathol; 2001 Sep; 116(3):410-9. PubMed ID: 11554170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of hepatosplenic T cell lymphoma in an adolescent with Turner syndrome using ifosfamide, carboplatin, and etoposide followed by allogeneic hematopoietic stem cell transplant.
    Lauhan CR; Schiff D; Gloude N
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28528. PubMed ID: 32776434
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): preliminary results from the T-Cell Consortium trial.
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 5):6-7. PubMed ID: 24852788
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
    Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
    Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate.
    Leitenberger JJ; Berthelot CN; Polder KD; Pro B; McLaughlin P; Jones D; Duvic M
    J Am Acad Dermatol; 2008 Mar; 58(3):480-4. PubMed ID: 18280345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.